Over five-year follow-up of oka/merck varicella vaccine recipients in 465 infants and adolescents

Pediatric Infectious Disease Journal

Volumn 14, Issue 10, 1995, Pages 874-879

  Clements, Dennis A ^a   Armstrong, Christine B ^a   Ursano, Amy M ^a   Moggio, Mary M ^a   Walter, Emmanuel B ^a   Wilfert, Catherine M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Break through varicella disease; Vaccine effectiveness; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE;

ADOLESCENT; ARTICLE; CHICKENPOX; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOGENICITY; INFANT; NORMAL HUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; VACCINATION;

ADOLESCENT; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 3, HUMAN; HUMAN; IMMUNIZATION SCHEDULE; INFANT; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; VIRAL VACCINES;

EID: 0028889759     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/00006454-199510000-00011     Document Type: Article

References (17)

1. Ross AH, Lencher E, Reitman G. Modification of chickenpox in family contacts by administration of gamma globulin. N Engl J Med 1962;267:369-76.
2. Preblud SR. Varicella: complications and costs. Pediatrics 1986;78(Suppl):728-35.
3. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
4. Guess HA, Broughton DD, Melton LJ, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78(Suppl):723-37.
5. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-five year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94:524-6.
6. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991;87:604-10.
7. Weibel RE, Kuter BJ, Neff BJ, et al. Live Oka/Merck varicella vaccine in healthy children: further clinical and laboratory assessment. JAMA 1985;254:2435-9.
8. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month- old children. Pediatrics 1988;81:512-8.
9. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984;310:1409-15.
10. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-7.
11. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chick- enpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
12. Bernstein HH, Rothstein EP, White CJ, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993;92:833-6.
13. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
14. Wasmuth EH, Miller WJ. A sensitive enzyme-linked immunosorbent assay (ELISA) for antibody to varicella-zoster virus (VZV) using purified VZV glycoprotein antigen. J Med Virol 1990;32:189-93.
15. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991;9:111-6.
16. Shehab Z, Brunell P. Enzyme-linked immunosorbent assay for susceptibility to varicella. J Infect Dis 1983;148:472-6.
17. Keller PM, Lonergan K, Neff BJ, et al. Purification of individual varicella-zoster virus (VZV) glycoproteins gpl, gpll, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 1986; 14: 177-88.